Skip to content
Biodatica
Start free

BioNTech SE

Grand Rapids, Michigan

OncologyvaccinePhase IIListed · BNTX

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers

4mo agoTrial registeredMar 18, 2026Source filing (opens the source filing in a new tab)

Momentum

80no change

Momentum 80 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Jul 1, 2024

    Bacterial Vaginosis · COMPLETED · sponsor: BioNTech SE · A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis

    ClinicalTrials.gov · NCT06469164 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Nov 30, 2023

    Advanced Malignant Solid Tumor · ACTIVE_NOT_RECRUITING · sponsor: BioNTech SE · Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors

    ClinicalTrials.gov · NCT06150183 (opens the source filing in a new tab)

  3. Trial

    PHASE1/PHASE2 registered

    Jul 31, 2023

    Tuberculosis · ACTIVE_NOT_RECRUITING · sponsor: BioNTech SE · Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers

    ClinicalTrials.gov · NCT05547464 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Apr 18, 2023

    Tuberculosis · COMPLETED · sponsor: BioNTech SE · Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers

    ClinicalTrials.gov · NCT05537038 (opens the source filing in a new tab)

  5. Trial

    PHASE1/PHASE2 registered

    Jan 26, 2021

    Solid Tumor · TERMINATED · sponsor: BioNTech SE · BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors

    ClinicalTrials.gov · NCT04455620 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources